Abstract 49P
Background
To date, miR-155 is known as an oncogenic miRNA with a well-documented role in breast cancer. Cancer stemness plays an important role in various aspects of carcinogenesis. The aim of this study is to investigate the effect of miR-155 on breast cancer proliferation by upregulating cancer stem cells.
Methods
In vivo-tumor growth and metastasis were measured across polyomavirus middle T antigen (PyVmT) transgenic mice and PyVmT miR-155 knockout mice. Western blot and quantitative real-time polymerase chain reaction (qRT-PCR) were employed to determine the protein and mRNA levels, respectively. The cancer stemness was assessed by sphere formation as well as the expression of the related markers. The miR-155 target genes were predicted and analyzed by western blot and luciferase assay.
Results
Upregulation of miR-155 in breast cancer tissues of mice identified poor prognosis and cancer metastasis. Upregulation of miR-155 was also found in breast cancer stem cells. Ectopic expression of miR-155 promotes the stemness of breast cancer cells. Conversely, depletion of miR-155 attenuates the stemness of these cells. miR-155 directly binds to CYLD and Sharp-1 to influence breast cancer stemness.
Conclusions
MicroRNA-155 promotes breast cancer progression by upregulating breast cancer stemness.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
94P - Harnessing circulating tumor DNA in bronchoalveolar lavage fluid for precise molecular diagnosis of NSCLC
Presenter: Frank Borm
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)
Presenter: Betzabel Cajiao Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in endometrial cancer (EC) patients
Presenter: Simona Duranti
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Prospects of liquid biopsy in determining prognosis in children with HGG and DIPG
Presenter: Olga Regentova
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Liquid biopsy in NSCLC: A promising tool to predict immunotherapy response
Presenter: Ana Fernández
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Comprehensive genomic sequencing as an ancillary diagnostic tool for pathologists
Presenter: Dan Miller
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Standard serum biomarkers to help predict a cancer diagnosis in patients with non-specific symptoms: Data from Guy´s rapid diagnostic clinic
Presenter: Maria Monroy Iglesias
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Patient-derived organoids to optimize CDK4/6 inhibitor-based treatment selection in early breast cancer
Presenter: Carla Alves
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - MicroRNAs in urine and saliva as non-invasive biomarkers of minimal residual disease in pediatric acute lymphoblastic leukemia
Presenter: Alejandra Pando-Caciano
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract